CR20150572A - Métodos para tratar la psoriasis utilizando un anticuerpo ant-il-23 - Google Patents

Métodos para tratar la psoriasis utilizando un anticuerpo ant-il-23

Info

Publication number
CR20150572A
CR20150572A CR20150572A CR20150572A CR20150572A CR 20150572 A CR20150572 A CR 20150572A CR 20150572 A CR20150572 A CR 20150572A CR 20150572 A CR20150572 A CR 20150572A CR 20150572 A CR20150572 A CR 20150572A
Authority
CR
Costa Rica
Prior art keywords
methods
treat psoriasis
products
antibody
psoriasis
Prior art date
Application number
CR20150572A
Other languages
English (en)
Spanish (es)
Inventor
Ll John P Gibbs
Wayne Tsuji
Wei-Jian Pan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50336511&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150572(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20150572A publication Critical patent/CR20150572A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
CR20150572A 2013-03-15 2015-10-15 Métodos para tratar la psoriasis utilizando un anticuerpo ant-il-23 CR20150572A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789777P 2013-03-15 2013-03-15
PCT/US2014/018293 WO2014149425A1 (en) 2013-03-15 2014-02-25 Methods for treating psoriasis using an anti-il-23 antibody

Publications (1)

Publication Number Publication Date
CR20150572A true CR20150572A (es) 2016-04-25

Family

ID=50336511

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150572A CR20150572A (es) 2013-03-15 2015-10-15 Métodos para tratar la psoriasis utilizando un anticuerpo ant-il-23

Country Status (17)

Country Link
US (3) US20160060337A1 (https=)
EP (2) EP3689369A1 (https=)
JP (4) JP2016517408A (https=)
KR (1) KR20150128858A (https=)
CN (1) CN105209064A (https=)
AP (1) AP2015008803A0 (https=)
AU (3) AU2014238148A1 (https=)
CA (1) CA2906382A1 (https=)
CL (1) CL2015002723A1 (https=)
CR (1) CR20150572A (https=)
EA (1) EA201591581A1 (https=)
HK (1) HK1219425A1 (https=)
IL (2) IL241342A0 (https=)
PH (2) PH12015502129A1 (https=)
SG (2) SG11201507482UA (https=)
TN (1) TN2015000403A1 (https=)
WO (1) WO2014149425A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
PL3326649T3 (pl) 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
EA202193002A2 (ru) 2014-09-03 2022-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23a и фно-альфа, и его применение
AU2016215535B2 (en) * 2015-02-04 2021-09-16 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
CN109071653A (zh) * 2016-03-29 2018-12-21 詹森生物科技公司 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
JP6728392B2 (ja) * 2016-04-15 2020-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性疾患の処置法
US20200025776A1 (en) * 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
CA3118964A1 (en) * 2018-11-05 2020-05-14 Merck Sharp & Dohme Corp. Dosing regimen of anti-tigit antibody for treatment of cancer
JP2022526493A (ja) * 2019-03-18 2022-05-25 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体を用いた小児被験者の乾癬の治療方法
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
SI2452694T1 (sl) 2005-06-30 2019-05-31 Janssen Biotech, Inc. Protitelesa proti-IL-23, sestavki in postopki uporabe
DE602006015830D1 (de) 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
US20070050011A1 (en) 2005-08-26 2007-03-01 Medlogics Device Corporation Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs
PT1931710T (pt) 2005-08-31 2017-03-28 Merck Sharp & Dohme Anticorpos anti-il-23 manipulados
CN101389769A (zh) * 2005-12-28 2009-03-18 森托科尔公司 用于评价和治疗银屑病及相关疾病的标记与方法
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2009117289A2 (en) * 2008-03-18 2009-09-24 Abbott Laboratories Methods for treating psoriasis
EP2301119B1 (en) 2008-06-30 2015-05-13 Black & Decker, Inc. Cord protector for power tools
EP2331078B1 (en) 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Lyophilized formulations of engineered anti-il-23p19 antibodies
US20120128689A1 (en) 2009-04-01 2012-05-24 Glaxo Group Limited Anti-il-23 immunoglobulins
US20120264917A1 (en) 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
SG179135A1 (en) * 2009-09-14 2012-05-30 Abbott Lab Methods for treating psoriasis
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
WO2012009760A1 (en) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
CN103813804A (zh) * 2010-10-06 2014-05-21 Abbvie公司 用于治疗银屑病的方法
CN103154031A (zh) * 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.

Also Published As

Publication number Publication date
CL2015002723A1 (es) 2016-03-28
HK1219425A1 (zh) 2017-04-07
PH12019502700A1 (en) 2020-12-07
CN105209064A (zh) 2015-12-30
AU2014238148A1 (en) 2015-10-08
IL241342A0 (en) 2015-11-30
AP2015008803A0 (en) 2015-10-31
CA2906382A1 (en) 2014-09-25
SG11201507482UA (en) 2015-10-29
EP2968488A1 (en) 2016-01-20
AU2019200206A1 (en) 2019-01-31
JP2023011815A (ja) 2023-01-24
JP2016517408A (ja) 2016-06-16
US20160060337A1 (en) 2016-03-03
SG10201804954UA (en) 2018-07-30
US20200277368A1 (en) 2020-09-03
TN2015000403A1 (en) 2017-01-03
JP2021102644A (ja) 2021-07-15
EA201591581A1 (ru) 2016-01-29
AU2020270495A1 (en) 2020-12-17
US20220135668A1 (en) 2022-05-05
JP2020063237A (ja) 2020-04-23
KR20150128858A (ko) 2015-11-18
EP3689369A1 (en) 2020-08-05
PH12015502129A1 (en) 2016-01-25
IL275093A (en) 2020-07-30
WO2014149425A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
CR20150572A (es) Métodos para tratar la psoriasis utilizando un anticuerpo ant-il-23
TN2015000402A1 (fr) Methods for treating crohn's disease using an anti-il23 antibody
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX2017001512A (es) Compuestos activos hacia bromodominios.
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
MX2018011348A (es) Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades.
BR112016023362A2 (pt) molécula de ligação ao antígeno triespecífica
MX390954B (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
BR112018000212A2 (pt) uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
MX394497B (es) Nanoportadores sintéticos tolerogénicos y macromoléculas terapéuticas para efectos farmacodinámicos reducidos o intensificados.
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
CL2017002334A1 (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
ECSP19000169A (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2016013236A (es) Formulacion inmunosupresora.
CL2015002692A1 (es) Novedosos compuestos de bencenosulfonamida, método para sintetizarlos y uso de los compuestos en medicina y en cosméticos.
AR100436A1 (es) Método y dispositivo para medir la permeabilidad de la dentina
MX394089B (es) Nuevos derivados de xantina sustituidos.
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
BR112016016269A2 (pt) Formulação de sais de re-hidratação lipossomal